Full Press Release Details
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure.
LXRX
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
Key Takeaway: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
Price reaction · baseline $2.9 (2023-05-25 close) · hit after-hours · 3 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
+9.7%
day 1
0%
day 3
-6.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus